Loading patent…
AssigneesMayo Foundation for Medical Education and Research, Abbott Molecular Inc.
InventorsIrina Sokolova, Larry Morrison, Ekaterina Pestova, Emily Barr Fricher, Lewis Roberts, Gregory Gores, Kevin Halling, Benjamin Kipp
Estimating the term…
A method of detecting high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract or inferring an increased risk thereof, comprising obtaining a sample of pancreatobiliary cells from a patient with a set of detectably labeled probes comprising a locus-specific probe for MCL1 (myeloid cell leukemia sequence 1), a locus-specific probe for EGFR (epidermal growth factor receptor), a locus-specific probe for MYC, and a locus-specific probe for P16 under hybridization conditions and determining the presence of chromosomal abnormalities; a set of probes comprising a locus-specific probe for MCL1, a locus-specific probe for EGFR, a locus-specific probe for MYC, and a locus-specific probe for P16; and a kit comprising the set of probes and instructions for detecting high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract, or inferring an increased risk thereof, in a patient.
A method of detecting high-grade dysplasia, pancreatobiliary cancer, metastatic cancer to the pancreatobiliary tract, or inferring an increased risk thereof, in a patient, which method comprises:
A set of probes comprising a locus-specific probe for MCL1 (myeloid cell leukemia sequence 1), a locus-specific probe for EGFR (epidermal growth factor receptor), a locus-specific probe for MYC, and a locus-specific probe for P16.
A kit comprising:
Dependencies are inferred from the claim text.